Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL304987 | 0.78 | CYP3A4 (0.33) | — | |
| SCHEMBL3764758 | 0.72 | — | — | |
| SCHEMBL14994712 | 0.72 | L3MBTL1 (0.33) | — | |
| SCHEMBL14797510 | 0.69 | CDK2 (0.44) | CDK2 | |
| SCHEMBL583753 | 0.69 | DGAT1 (0.33) | — | |
| SCHEMBL1502646 | 0.68 | CYP19A1 (0.31) | — | |
| SCHEMBL117688 | 0.68 | ENPP2 (0.43) | — | |
| SCHEMBL574865 | 0.68 | CYP19A1 (0.32) | — | |
| SCHEMBL15533777 | 0.68 | KDM4E (0.31) | — | |
| SCHEMBL4353461 | 0.68 | GAA (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200325154-A1 | ANTIBACTERIAL BIAROMATIC DERIVATIVES WITH OXETANE-3-YLOXY SUBSTITUTION | ACTELION PHARMACEUTICALS LTD (CH) | 2020-10-15 | — | — | US | disclosed |
| EP-3442970-A1 | ANTIBACTERIAL BIAROMATIC DERIVATIVES WITH OXETANE-3-YLOXY SUBSTITUTION | Idorsia Pharmaceuticals Ltd (CH) | 2019-02-20 | — | — | EP | disclosed |
| WO-2017179002-A1 | ANTIBACTERIAL BIAROMATIC DERIVATIVES WITH OXETANE-3-YLOXY SUBSTITUTION | ACTELION PHARMACEUTICALS LTD (CH) | 2017-10-19 | — | — | WO | disclosed |
| EP-2086970-B1 | 2-(PYRAZIN-2-YL)-THIAZOLE AND 2-(1H PYRAZOL-3-YL)-THIAZOLE DERIVATIVES AS WELL AS RELATED COMPOUNDS AS STEAROYL-COA DESATURASE (SCD) INHIBITORS FOR THE TREATMENT OF METABOLIC, CARDIOVASCULAR AND OTHER DISORDERS | NOVARTIS AG (CH) | 2014-02-26 | — | — | EP | disclosed |
| US-8314138-B2 | Pyrazole derivative as SCD1 inhibitors for the treatment of diabetes | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20100239520-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239520-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | CDK2 1245/4885 |
| US-20200325154-A1 | ANTIBACTERIAL BIAROMATIC DERIVATIVES WITH OXETANE-3-YLOXY SUBSTITUTION | MT-CO3, UQCRC1, MT-ND3 | CDK2 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.